Autosomal recessive progeroid syndrome due to homozygosity for a TOMM7 variant is a research paper published in Journal of Clinical Investigation (2022). On theSindex it has a DataRank of 0. It has been cited 34 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NIH-NATIONAL INSTITUTE OF DDK DISEASES
Grant: 5RO1DK105448
NIEHS NIH HHS
Grant: DP2 ES030449
NIDDK NIH HHS
Grant: F31 DK122676
NIAMS NIH HHS
Grant: R01 AR073217
NIDDK NIH HHS
Grant: R01 DK105448
National Institutes of Health
Grant: 1F31DK122676-01A1
Examining Transsulfuration in Mitochondrial Hepatopathy in vivo
National Institutes of Health
Grant: 5R01AR073217-03
Deciphering the role of amino acid transporters in mitochondrial myopathy
National Institutes of Health
Grant: 5R01DK105448-07
Genetic and Metabolic Basis of Familial Lipodystrophies
National Institutes of Health
Grant: 1DP2ES030449-01
Engineering faithful animal models of mitochondrial disease
Fields of Study
MeSH Terms
Keywords
Additional file 1 of MyD88 dimerization inhibitor ST2825 targets the aggressiveness of synovial fibroblasts in rheumatoid arthritis patients
Additional file 1 of MyD88 dimerization inhibitor ST2825 targets the aggressiveness of synovial fibroblasts in rheumatoid arthritis patients
Additional file 2 of MyD88 dimerization inhibitor ST2825 targets the aggressiveness of synovial fibroblasts in rheumatoid arthritis patients
Additional file 3 of MyD88 dimerization inhibitor ST2825 targets the aggressiveness of synovial fibroblasts in rheumatoid arthritis patients
Additional file 2 of MyD88 dimerization inhibitor ST2825 targets the aggressiveness of synovial fibroblasts in rheumatoid arthritis patients
Additional file 3 of MyD88 dimerization inhibitor ST2825 targets the aggressiveness of synovial fibroblasts in rheumatoid arthritis patients